United States-based global pharmaceutical company MSD said on Monday that China's National Medical Products Administration has approved the use of multiple new indications of Gardasil®9, its ...

MSD's Gardasil®9, a nine-valent HPV vaccine, is approved for use in males between 16 and 26 years old by China's National Medical Products Administration on Monday. [Photo provided to chinadaily ...

MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeutics Cyprumed will be eligible to receive up to $493 million in upfront, development ...

In its Q2 2024 earnings, MSD announced that sales for Gardasil were 17% lower (18% in exchange) compared to the previous year. At the time, the company attributed this to broader market headwinds ...

MSD Pharmaceuticals' Gardasil 4 vaccine and Serum Institute's Cervavac are quadrivalent vaccines that target four HPV sub-types -- 6, 11, 16 and 18. MSD's Gardasil 9, which is India's first gender ...

MSD Pharmaceuticals' Gardasil 4 vaccine and Serum Institute's Cervavac are quadrivalent vaccines that target four HPV sub-types -- 6, 11, 16 and 18. MSD's Gardasil 9, which is India's first gender ...

GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1 ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non ...

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year.

Sign up to receive important email messages about the Imagine RIT Festival this year, and future years, too (save-the-date announcement, event announcements, and post ...